Powered by

Aquinnah Pharmaceuticals Receives $750,000 Grant from the Alzheimer's Association and Tau Consortium to Advance New Therapies for Tauopathy Diseases

Jan 17, 2019 - PR Newswire

PR Newswire

Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, announced today that it has been awarded $750,000 from the Tau Pipeline Enabling Program (T-PEP) to advance its drug development programs in tauopathy diseases, including Progressive Supranuclear Palsy, Alzheimer's Disease, and Fronto-temporal Dementia.T-PEPis a partnership between theAlzheimer's Associationand theTau Consortium; a program of the Rainwater Chari...